Aon backs eMed

eMed  has raised $200 million at a valuation exceeding $2 billion, positioning itself as a platform focused on employer-sponsored population health, particularly around GLP-1 and GIP therapies.

The round was led by Aon Consulting, with participation from a mix of institutional and strategic investors, including Tom Brady, who also serves as founding chief wellness officer, alongside investors tied to healthcare, private equity, and technology.

eMed offers clinically supervised weight management programs centered on GLP-1 medications, targeting employers looking to offer these benefits at scale. The company reports over 90% adherence rates, significantly above typical industry levels, with members seeing measurable outcomes such as average weight loss and biomarker improvements within six months.

The funding will support further development of its AI-driven platform and expansion of a capitated care model aimed at reducing employer healthcare costs. The move comes as demand for GLP-1 coverage grows, with many employers still lacking access to structured programs despite strong employee interest.